Phillip Ginsberg, DO
Urology · Philadelphia, PANPI 1902882715
Payments from drug & device makers
Across 972 payments — averaging $149.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$62K
- Sumitomo Pharma America, Inc.$54K
- Ferring Pharmaceuticals Inc.$7K
- Amgen$4K
- Johnson & Johnson$2K
- Astellas Pharma US Inc$2K
- plus $13K from 49 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$144,921 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Philadelphia
- Costas LallasPhiladelphia$3.6M
- Stanley MalkowiczPhiladelphia$882K
- Demetrius BagleyPhiladelphia$739K
- Gregory TasianPhiladelphia$645K
- Eugene PietzakPhiladelphia$544K
- Philip AbboshPhiladelphia$472K
- Trinity BivalacquaPhiladelphia$361K
- Edouard TrabulsiPhiladelphia$254K
- Paul ChungPhiladelphia$242K
- Daniel EunPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.